Edition:
United Kingdom

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.08USD
15 Dec 2017
Change (% chg)

$-0.14 (-6.31%)
Prev Close
$2.22
Open
$2.23
Day's High
$2.23
Day's Low
$2.06
Volume
101,183
Avg. Vol
67,865
52-wk High
$4.25
52-wk Low
$0.78

Select another date:

Fri, Dec 8 2017

BRIEF-Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer

* AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER

BRIEF-Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA

* AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY

BRIEF-Aeterna Zentaris reports Q3 loss per share of $0.61

* Aeterna Zentaris reports third quarter 2017 financial and operating results

BRIEF-Aeterna Zentaris announces appointment of interim chief financial officer

* Aeterna zentaris announces appointment of interim chief financial officer

BRIEF-Aeterna Zentaris reports Q2 loss per share $0.18

* Aeterna Zentaris reports second quarter 2017 financial and operating results

BRIEF-Aeterna Zentaris engages advisors and provides update to shareholders

* Aeterna Zentaris engages advisors and provides update to shareholders

BRIEF-David Dodd responds to claim filed by Aeterna Zentaris

* David Dodd, former CEO of Aeterna Zentaris, responds to claim filed by Aeterna Zentaris against him & Philip Theodore​

BRIEF-Aeterna Zentaris files claim against former CEO, former general counsel

* Aeterna Zentaris commences legal action against David Dodd and Philip Theodore

BRIEF-Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​

* Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO

BRIEF-NDA for Aeterna Zentaris' Macrilen granted PDUFA date

* NDA for Macrilen for the evaluation of growth hormone deficiency in adults granted December 30, 2017 PDUFA date

Select another date: